...
首页> 外文期刊>European journal of mass spectrometry >Application of selected reaction monitoring and parallel reaction monitoring for investigation of HL-60 cell line differentiation
【24h】

Application of selected reaction monitoring and parallel reaction monitoring for investigation of HL-60 cell line differentiation

机译:选定的反应监测和平行反应监测在HL-60细胞系分化研究中的应用

获取原文
获取原文并翻译 | 示例

摘要

Targeted mass spectrometry represents a powerful tool for investigation of biological processes. The convenient approach of selected reaction monitoring using stable isotope-labeled peptide standard (SIS) is widely applied for protein quantification. Along with this method, high-resolution parallel reaction monitoring has been increasingly used for protein targeted analysis. Here we applied two targeted approaches (selected reaction monitoring with SIS and label-free parallel reaction monitoring) to investigate expression of 11 proteins during all-trans retinoic acid-induced differentiation of HL-60 cells. In our experiments, we have determined the proteins expression ratio at 3, 24, 48, and 96 h after all-trans retinoic acid treatment in comparison with 0 h, respectively. Expression profiles of four proteins (VAV1, PRAM1, LYN, and CEBPB) were highly correlated (r> 0.75) and FGR expression was detected on proteome level starting from 24 h by both techniques. For prominent differences (fold change >= 2) label-free parallel reaction monitoring is not inferior to selected reaction monitoring with isotopically labeled peptide standards. Differentially expressed proteins, that have been determined in our study, can be considered as potential drug targets for acute myeloid leukemia (AML) treatment.
机译:靶向质谱是一种强大的工具,用于调查生物过程。使用稳定同位素标记的肽标准(SIS)的所选反应监测的方便方法广泛应用于蛋白质量化。除此之外,高分辨率平行反应监测越来越多地用于蛋白质靶向分析。在这里,我们应用了两种靶向方法(使用SIS和无标记并行反应监测的选定反应监测),以研究HL-60细胞的全反式视黄酸诱导的分化期间11个蛋白质的表达。在我们的实验中,我们已经确定了与0h的全反式视黄酸处理后3,24,48和96小时的蛋白质表达比。四种蛋白质(VAV1,PRAM1,LIN和CEBPB)的表达谱具有高度相关的(R> 0.75),并且在两种技术开始于24小时的蛋白质组水平上检测FGR表达。对于突出差异(折叠变化> = 2)无标记的并联反应监测不差不等于具有同位素标记的肽标准的选择反应监测。已经在我们的研究中确定的差异表达蛋白质可以被认为是急性髓性白血病(AML)治疗的潜在药物靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号